Novartis Teams Up With Sangamo In Brain Gene Therapy Pact
Autism At The Center of Collaboration
Novartis is the latest big pharma to sign up for access to Sangamo's gene therapy technologies, inking a deal that will focus on neurodevelopment disorders and could be worth in the region of $800m.
You may also be interested in...
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
Novartis has terminated development of three mid- to late-stage pipeline projects, Scrip discovered after comparing the company's 1Q 2014 and 4Q 2013 results. The dropped products include secukinumab in its uveitis indication, a Phase IIb/III product to treat fragile X syndrome, and a Phase II drug to treat Clostridium difficile infection.
Tecentriq is the only checkpoint inhibitor to get approval for first-line TNBC but failure in a second study for that indication will encourage rival Merck & Co with Keytruda nearing approval.